This education day focuses on CAR T clinical trials within the field of autoimmune conditions, bringing together a range of expert speakers from across Scotland and the UK.

This 90-minute session will feature four case study presentations from experienced clinical sites, highlighting how they have developed local capability and infrastructure to support CAR T trials in autoimmune indications.

Discover how the ATTC network is supporting training and education of NHS staff for advanced therapy trials.

Only slides are available There is a very strong global optimism regarding the immediate future of cell and gene therapy and the UK Ecosystem generally is ‘punching above its weight’. Where will the UK feature over the next 10 years and what will be needed to optimise our contribution to transformative medical treatment and economic benefit? This webinar addresses critical…

Only slides from the event are available Involving patients in the development of ATMPs is a key part of improving outcomes for patients. This webinar explores the rationale around why patient and public engagement is essential in the development of new therapies, focusing on the specific challenges and needs for cell and gene therapy and the benefits to patient and…

Only slides are available. The presentation focuses on the impact that the work of UK Advanced Therapies has had including a number of case studies.

Only slides from the event are available The quality and safety of Advanced Therapy Medicinal Products (ATMPs) are contingent on that of their starting materials, particularly where these are substance of human origin such as mononuclear cells (MNCs) procured by apheresis. Across the UK there are over 50 Clinical Apheresis Units (CAUs) operating under a Human Tissue Authority (HTA) collecting starting material…

Only slides are available   It is well known that there are substantial challenges for the development and clinical supply of Advanced Therapy Medicinal products (ATMP).  These  span many different themes: complex regulatory pathways; unfamiliar clinical procurement practices; novel biology; limited data to justify reimbursement; high cost of goods, to name just a few. As such it is important for…

Only slides from the event are available Due to the unique nature of cell or tissue-based ATMPs, there may be occasions when the manufactured medicine is not in full compliance with the release specification, yet it may be in the patient’s best interest to allow administration of the out-of-specification (OOS) medicine.  Administration of OOS ATMPs is exceptionally permissible from a…

Only slides are available

Only slides from the event are available

Only slides are available

Only slides are available

Follow link to register https://event.on24.com/wcc/r/2973904/D5E203A48AE3120A09637F9C70B27C03

Only slides are available Follow this link to register for the event

The clinical development of Advanced Therapy Medicinal Products (ATMPs) presents unique challenges. Whilst they may be transformative for patients, their optimal design, clinical delivery and long-term benefits are still to be determined. Innovative clinical trial design allows for trials to be adapted to emerging clinical data and manufacturing innovation resulting in potential improved speed and efficiency of trials, shortened time to market and ultimately accelerating patient access to treatments.
Also central to this work is the ability to assess and improve institutional readiness (IR) of hospitals and clinics to implement this innovation in the clinical delivery of ATMPs as more of these new therapies enter clinical studies and reach market authorisation. Such innovation requires close collaboration between developers, regulators, payers and clinical trial sites to ensure evidence requirements are met.

The Cell and Gene Therapy Catapult, Association of British Pharmaceutical Industry (ABPI) and UK BioIndustry Association (BIA) jointly invite you to explore the interfaces in these collaborations and to specifically identify and discuss areas for improvements and key recommendations.

The clinical development of Advanced Therapy Medicinal Products (ATMPs) presents unique challenges. Whilst they may be transformative for patients, their optimal design, clinical delivery and long-term benefits are still to be determined. Innovative clinical trial design allows for trials to be adapted to emerging clinical data and manufacturing innovation resulting in potential improved speed and efficiency of trials, shortened time to market and ultimately accelerating patient access to treatments.
Also central to this work is the ability to assess and improve institutional readiness (IR) of hospitals and clinics to implement this innovation in the clinical delivery of ATMPs as more of these new therapies enter clinical studies and reach market authorisation. Such innovation requires close collaboration between developers, regulators, payers and clinical trial sites to ensure evidence requirements are met.
The Cell and Gene Therapy Catapult, Association of British Pharmaceutical Industry (ABPI) and UK BioIndustry Association (BIA) jointly invite you to explore the interfaces in these collaborations and to specifically identify and discuss areas for improvements and key recommendations.

Gene therapy shows great promise for treating many diseases and is a rapidly growing field. Several gene therapies are now licensed medicines and the number is steadily increasing. This webinar provides an introduction to gene therapy and is of interest to anyone involved in either treating patients with gene therapy or looking after patients that have received gene therapy.

This day is looking to develop a consensus of what ‘good practice’ looks like and understand the key parameters for use of flow cytometry as part of quality control​ in the production of cell therapies. If you are interested in this meeting please get in touch at   ​attc@ct

This day is looking to develop a consensus of what ‘good practice’ looks like and understand the key parameters for use of flow cytometry as part of quality control​ in the production of cell therapies. If you are interested in this meeting please get in touch at   ​attc@ct

The workshop will present an opportunity to scope the creation of a 'Northern Network' of Advanced Therapy researchers. We will hear about current Advanced Therapy research being undertaken in the North of England and also discuss the current challenges being faced.

The workshop will present an opportunity to scope the creation of a 'Northern Network' of Advanced Therapy researchers. We will hear about current Advanced Therapy research being undertaken in the North of England and also discuss the current challenges being faced.

As part of Boston Biotech Week 2019, the ATTC Network is taking part in the Cell and Gene Therapy Bioprocessing & Commercialization conference hosted by knect365 at the Boston Convention and Exhibition Center (BCEC).   Anna Outhwaite, CGT Catapult will discuss the challenges for adoption of advanced therapies and the experience from the UK. You can listen to Anna's talk…

As part of Boston Biotech Week 2019, the ATTC Network is taking part in the Cell and Gene Therapy Bioprocessing & Commercialization conference hosted by knect365 at the Boston Convention and Exhibition Center (BCEC).   Anna Outhwaite, CGT Catapult will discuss the challenges for adoption of advanced therapies and the experience from the UK. You can listen to Anna's talk…

Organising and initiating clinical studies is highly complex. This is even more difficult with trials investigating advanced therapies. The pathway to obtain regulatory, GMO and ethical permission to commence studies with ATMPs can be challenging. Identifying suitable sites for studies that can accommodate the requirements for the administration of ATMPs may also be difficult. These trials also have challenging designs…

Organising and initiating clinical studies is highly complex. This is even more difficult with trials investigating advanced therapies. The pathway to obtain regulatory, GMO and ethical permission to commence studies with ATMPs can be challenging. Identifying suitable sites for studies that can accommodate the requirements for the administration of ATMPs may also be difficult. These trials also have challenging designs…

Venue: Boiler Shop, Newcastle upon Tyne Register here You are invited to join us at Northern Alliance Advanced Therapies Treatment Centre’s (NAATTC) ‘Reflections on Advanced Therapy Delivery’ meeting. The event aims to promote the visibility of the NAATTC and its activities so far, foster engagement with the wider Advanced Therapy (AT) community and share best practice. There will be a…

Venue: Boiler Shop, Newcastle upon Tyne Register here You are invited to join us at Northern Alliance Advanced Therapies Treatment Centre’s (NAATTC) ‘Reflections on Advanced Therapy Delivery’ meeting. The event aims to promote the visibility of the NAATTC and its activities so far, foster engagement with the wider Advanced Therapy (AT) community and share best practice. There will be a…

Come and meet us at stand 45 to find out more about the latest projects and updates from the ATTC Network!   Dr Jacqueline Barry, CGT Catapult is leading a pre-conference workshop on 15th May, titled 'Clinical trial focus workshop'.   Dr Barry is also chairing the Cell Therapy Trials track on 16th May and leading the panel discussion, 'Advanced…

Immuno-Oncology Summit Europe 2019 Cambridge Healthtech Institute’s Fourth Annual Immuno-Oncology Summit Europe returns to London for a week of cutting-edge science and discussion. Through six conference tracks, delegates will hear from the research teams at the forefront of the rapidly developing field of cancer biotherapeutics. As part of the Adoptive T-Cell Therapy track, Dr Jacqueline Barry, Chief Clinical Officer at CGT…

Clinical trials are an essential part of developing advanced therapies and accelerating their progression for patient benefit. The event will cover various aspects of how to design and conduct effective clinical trials in this fast-growing area.  Attendees will have the opportunity to listen to experts in the field and debate what makes a clinical trial successful. The ATTC Network will…

Clinical trials are an essential part of developing advanced therapies and accelerating their progression for patient benefit. The event will cover various aspects of how to design and conduct effective clinical trials in this fast-growing area.  Attendees will have the opportunity to listen to experts in the field and debate what makes a clinical trial successful. The ATTC Network will…

On 12th February 2019, at Alderley Park, we are pleased to announce the opening of registration for the ImmunoOncology One Mnachster Confernce This 1 day event for150-200 participants from Industry, Academia and NHS Trusts is designed to showcase our current Manchester strengths and encourage new and exciting collaborations. The day will be split into three sessions and will include speakers…

On 12th February 2019, at Alderley Park, we are pleased to announce the opening of registration for the ImmunoOncology One Mnachster Confernce This 1 day event for150-200 participants from Industry, Academia and NHS Trusts is designed to showcase our current Manchester strengths and encourage new and exciting collaborations. The day will be split into three sessions and will include speakers…

Phacilitate Leaders World and the World Stem Cell Summit 2019 will once again be co-located in Miami. You can view the full agenda online. The ATTC network will be represented by Dr Jacqueline Barry, Chief Clinical Officer at Cell and Gene Therapy Catapult in two separate sessions: Wednesday 23 January, 1:35pm Dr Jacqueline Barry, Chief Clinical Officer Roundtable chair: Forging the path to standardised…

Phacilitate Leaders World and the World Stem Cell Summit 2019 will once again be co-located in Miami. You can view the full agenda online. The ATTC network will be represented by Dr Jacqueline Barry, Chief Clinical Officer at Cell and Gene Therapy Catapult in two separate sessions: Wednesday 23 January, 1:35pm Dr Jacqueline Barry, Chief Clinical Officer Roundtable chair: Forging the path to standardised…

You are cordially invited to take part in this exciting international conference that brings to you key note speakers from the UK, Canada, USA, Spain, Denmark and Ireland. Patient and Public Involvement (PPI) – also referred to as ‘Patient and Public Engagement’ and ‘Citizen Engagement’ by international colleagues - is the practice or process of patients, members of the public…

You are cordially invited to take part in this exciting international conference that brings to you key note speakers from the UK, Canada, USA, Spain, Denmark and Ireland. Patient and Public Involvement (PPI) – also referred to as ‘Patient and Public Engagement’ and ‘Citizen Engagement’ by international colleagues - is the practice or process of patients, members of the public…

Hosted by World Courier, this webinar will explore Scalable Logistics for Cell and Gene Therapies

Hosted by World Courier, this webinar will explore Scalable Logistics for Cell and Gene Therapies